- ABBV +0.28%
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Yahoo Finance · 1 day ago
Abbott Laboratories
Search results
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives.
- 166.56Add to watchlist+0.47 (+0.28%)At close:4:00 PM EDTThu. Jun 13, 2024166.56 0.00 (0.00%)After hrs:7:31 PM EDTThu. Jun 13, 2024Nasdaq Real Time Price (USD) · Market closed
- Open166.00High166.90Low165.00
- Mkt Cap294.12BP/E (TTM)49.57Div & Yield6.20 & 3.73%
- Prev. Close166.0952 Wk. Low130.9652 Wk. High182.89
What analysts are sayingTop storiesRelated stocks
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Apr 18, 2022 · AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74.
May 7, 2024 · AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. AbbVie and Alpine have entered into an exclusive worldwide option and license agreement for ALPN-101.
AbbVie is a global biopharmaceutical company with focus and capabilities to address some of the world's greatest health challenges. AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives.
May 7, 2024 · Our Patient Assistance Programs are intended for people that live in the United States, have limited or no health insurance coverage and demonstrate qualifying financial need. In 2022, we assisted nearly 200,000 people. Applying to myAbbVie Assist is simple.
Feb 12, 2024 · AbbVie Completes Acquisition of ImmunoGen. Adds flagship antibody-drug conjugate (ADC) ELAHERE® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio. ImmunoGen's pipeline complements AbbVie's existing oncology pipeline with potential to be transformative ...
